Status:
COMPLETED
A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The goal of the study is to learn what happens to levels of MK-0616 in the blood when MK-0616 is given in different forms. Researchers believe that there is no effect on a healthy person's body if MK-...
Eligibility Criteria
Inclusion
- The key inclusion criteria include but are not limited to the following:
- Is in good health before randomization
- Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive
Exclusion
- The key exclusion criteria include but are not limited to the following:
- Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- Has a history of cancer with pre-specified exceptions (adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies that have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study, per protocol guidelines)
Key Trial Info
Start Date :
October 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 29 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06592339
Start Date
October 25 2022
End Date
December 29 2022
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QPS-MRA, LLC-Early Phase
South Miami, Florida, United States, 33143